Kentaro Onishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kentaro Onishi has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- José Fábio Lana
Department of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil
3 shared publications - King Hei Stanley Lam
13 Faculty of Medicine, The Chinese University of Hong Kong, New Territories, HKG
3 shared publications - Peter Albert Everts
Medical School (GBCS), The University of Queensland, Brisbane, QLD 4006, Australia
3 shared publications - André van Zundert
Medical School (GBCS), The University of Queensland, Brisbane, QLD 4006, Australia
2 shared publications - Daniel Chiung-Jui Su
The Board of Clinical Research, The International Association of Musculoskeletal Medicine, Kowloon, Hong Kong, China
2 shared publications - Don Buford
Texas Orthobiologics, 1015 North Carroll, Suite 2000, Dallas, TX 75204, USA
2 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2382
Ultrasound-Guided Posteromedial Fascial–Periarticular Injection for Mild-to-Moderate Knee Osteoarthritis: Twelve-Month WOMAC Outcomes in a Retrospective Pilot Case Series
Knee osteoarthritis (OA) is increasingly recognized as a whole-joint disorder involving periarticular soft tissues in addition to intra-articular structures. A recently published technical report described an ultrasound-guided posteromedial knee injection targeting a fascial–periarticular convergence region operationally termed the popliteal fascial retinaculum. In the present study, we evaluated preliminary longitudinal clinical outcomes after this procedure in patients with mild-to-moderate knee OA. Background/Objectives: Knee OA is a common cause of chronic pain, stiffness, and disability. In the present study, we evaluated preliminary 12-month WOMAC outcomes after a three-session ultrasound-guided posteromedial fascial–periarticular injection in patients with Kellgren–Lawrence grade 1–3 knee OA. Methods: This retrospective analysis of a prospectively maintained single-center clinical registry included 10 patients treated between October 2023 and October 2025. Each patient received three monthly ultrasound-guided posteromedial injections using 30 mL of 5% dextrose with 0.1% lidocaine (lignocaine). The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was recorded at baseline and at 1, 3, 6, and 12 months after the final injection. Data are mean ± SD, median (IQR), and 95% CI. In exploratory inferential analyses, we used Friedman tests and Wilcoxon signed-rank tests with Bonferroni correction. Results: The mean WOMAC total score improved from 59.5 ± 4.33 at baseline to 38.6 ± 4.50 at 1 month, 34.3 ± 4.45 at 3 months, 30.6 ± 3.06 at 6 months, and 28.5 ± 2.51 at 12 months after the final injection, corresponding to a mean 12-month within-patient change of −31.0 points (95% CI −32.58 to −29.42; −52.1%). Mean pain improved from 12.6 ± 1.35 to 5.6 ± 0.70, stiffness from 4.7 ± 0.48 to 2.1 ± 0.32, and physical function from 42.2 ± 2.62 to 20.8 ± 2.15. All 10 patients had lower WOMAC total scores at 12 months than at baseline. Friedman tests were significant for all four WOMAC domains (all p ≤ 5.05 × 10−7); Wilcoxon signed-rank tests versus baseline reached the theoretical minimum p at n = 10 (Bonferroni-adjusted p = 7.81 × 10−3) at every follow-up timepoint. No serious adverse events were documented; mild transient post-procedural soreness occurred in three patients. Conclusions: In this small retrospective pilot cohort, ultrasound-guided posteromedial fascial–periarticular injection was associated with sustained improvement in WOMAC pain, stiffness, physical function, and total scores over 12 months. These findings are preliminary and hypothesis-generating; non-specific effects including placebo, regression to the mean, and natural symptomatic fluctuation cannot be excluded. Prospective controlled trials are required to establish safety, reproducibility, mechanism, and comparative effectiveness.
- 29 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2382
Open AccessUltrasound-Guided Posteromedial Fascial–Periarticular Injection for Mild-to-Moderate Knee Osteoarthritis: Twelve-Month WOMAC Outcomes in a Retrospective Pilot Case Series
Knee osteoarthritis (OA) is increasingly recognized as a whole-joint disorder involving periarticular soft tissues in addition to intra-articular structures. A recently published technical report described an ultrasound-guided posteromedial knee injection targeting a fascial–periarticular convergence region operationally termed the popliteal fascial retinaculum. In the present study, we evaluated preliminary longitudinal clinical outcomes after this procedure in patients with mild-to-moderate knee OA. Background/Objectives: Knee OA is a common cause of chronic pain, stiffness, and disability. In the present study, we evaluated preliminary 12-month WOMAC outcomes after a three-session ultrasound-guided posteromedial fascial–periarticular injection in patients with Kellgren–Lawrence grade 1–3 knee OA. Methods: This retrospective analysis of a prospectively maintained single-center clinical registry included 10 patients treated between October 2023 and October 2025. Each patient received three monthly ultrasound-guided posteromedial injections using 30 mL of 5% dextrose with 0.1% lidocaine (lignocaine). The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was recorded at baseline and at 1, 3, 6, and 12 months after the final injection. Data are mean ± SD, median (IQR), and 95% CI. In exploratory inferential analyses, we used Friedman tests and Wilcoxon signed-rank tests with Bonferroni correction. Results: The mean WOMAC total score improved from 59.5 ± 4.33 at baseline to 38.6 ± 4.50 at 1 month, 34.3 ± 4.45 at 3 months, 30.6 ± 3.06 at 6 months, and 28.5 ± 2.51 at 12 months after the final injection, corresponding to a mean 12-month within-patient change of −31.0 points (95% CI −32.58 to −29.42; −52.1%). Mean pain improved from 12.6 ± 1.35 to 5.6 ± 0.70, stiffness from 4.7 ± 0.48 to 2.1 ± 0.32, and physical function from 42.2 ± 2.62 to 20.8 ± 2.15. All 10 patients had lower WOMAC total scores at 12 months than at baseline. Friedman tests were significant for all four WOMAC domains (all p ≤ 5.05 × 10−7); Wilcoxon signed-rank tests versus baseline reached the theoretical minimum p at n = 10 (Bonferroni-adjusted p = 7.81 × 10−3) at every follow-up timepoint. No serious adverse events were documented; mild transient post-procedural soreness occurred in three patients. Conclusions: In this small retrospective pilot cohort, ultrasound-guided posteromedial fascial–periarticular injection was associated with sustained improvement in WOMAC pain, stiffness, physical function, and total scores over 12 months. These findings are preliminary and hypothesis-generating; non-specific effects including placebo, regression to the mean, and natural symptomatic fluctuation cannot be excluded. Prospective controlled trials are required to establish safety, reproducibility, mechanism, and comparative effectiveness.
- Open Access
- 24 July 2026
- Published by MDPI AG in Preprints.org
Ultrasound-Guided Posteromedial Fascial-Periarticular Injection for Mild-to-Moderate Knee Osteoarthritis: Twelve-Month WOMAC Outcomes in a Retrospective Pilot Case Series
Knee osteoarthritis (OA) is increasingly recognized as a whole-joint disorder involving periarticular soft tissues in addition to intra-articular structures. A recently published technical report described an ultrasound-guided posteromedial knee injection targeting a fascial–periarticular convergence region operationally termed the popliteal fascial retinaculum. In the present study, we evaluated preliminary longitudinal clinical outcomes after this procedure in patients with mild-to-moderate knee OA. Background/Objectives: Knee OA is a common cause of chronic pain, stiffness, and disability. In the present study, we evaluated preliminary 12-month WOMAC outcomes after a three-session ultrasound-guided posteromedial fascial–periarticular injection in patients with Kellgren–Lawrence grade 1–3 knee OA. Methods: This retrospective analysis of a prospectively maintained single-center clinical registry included 10 patients treated between October 2023 and October 2025. Each patient received three monthly ultrasound-guided posteromedial injections using 30 mL of 5% dextrose with 0.1% lidocaine (lignocaine). The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was recorded at baseline and at 1, 3, 6, and 12 months after the final injection. Data are mean ± SD, median (IQR), and 95% CI. In exploratory inferential analyses, we used Friedman tests and Wilcoxon signed-rank tests with Bonferroni correction. Results: The mean WOMAC total score improved from 59.5 ± 4.33 at baseline to 38.6 ± 4.50 at 1 month, 34.3 ± 4.45 at 3 months, 30.6 ± 3.06 at 6 months, and 28.5 ± 2.51 at 12 months after the final injection, corresponding to a mean 12-month within-patient change of −31.0 points (95% CI −32.58 to −29.42; −52.1%). Mean pain improved from 12.6 ± 1.35 to 5.6 ± 0.70, stiffness from 4.7 ± 0.48 to 2.1 ± 0.32, and physical function from 42.2 ± 2.62 to 20.8 ± 2.15. All 10 patients had lower WOMAC total scores at 12 months than at baseline. Friedman tests were significant for all four WOMAC domains (all p ≤ 5.05 × 10−7); Wilcoxon signed-rank tests versus baseline reached the theoretical minimum p at n = 10 (Bonferroni-adjusted p = 7.81 × 10−3) at every follow-up timepoint. No serious adverse events were documented; mild transient post-procedural soreness occurred in three patients. Conclusions: In this small retrospective pilot cohort, ultrasound-guided posteromedial fascial–periarticular injection was associated with sustained improvement in WOMAC pain, stiffness, physical function, and total scores over 12 months. These findings are preliminary and hypothesis-generating; non-specific effects including placebo, regression to the mean, and natural symptomatic fluctuation cannot be excluded. Prospective controlled trials are required to establish safety, reproducibility, mechanism, and comparative effectiveness.
- 24 July 2026
- Published by MDPI AG in Preprints.org
Open AccessUltrasound-Guided Posteromedial Fascial-Periarticular Injection for Mild-to-Moderate Knee Osteoarthritis: Twelve-Month WOMAC Outcomes in a Retrospective Pilot Case Series
Knee osteoarthritis (OA) is increasingly recognized as a whole-joint disorder involving periarticular soft tissues in addition to intra-articular structures. A recently published technical report described an ultrasound-guided posteromedial knee injection targeting a fascial–periarticular convergence region operationally termed the popliteal fascial retinaculum. In the present study, we evaluated preliminary longitudinal clinical outcomes after this procedure in patients with mild-to-moderate knee OA. Background/Objectives: Knee OA is a common cause of chronic pain, stiffness, and disability. In the present study, we evaluated preliminary 12-month WOMAC outcomes after a three-session ultrasound-guided posteromedial fascial–periarticular injection in patients with Kellgren–Lawrence grade 1–3 knee OA. Methods: This retrospective analysis of a prospectively maintained single-center clinical registry included 10 patients treated between October 2023 and October 2025. Each patient received three monthly ultrasound-guided posteromedial injections using 30 mL of 5% dextrose with 0.1% lidocaine (lignocaine). The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was recorded at baseline and at 1, 3, 6, and 12 months after the final injection. Data are mean ± SD, median (IQR), and 95% CI. In exploratory inferential analyses, we used Friedman tests and Wilcoxon signed-rank tests with Bonferroni correction. Results: The mean WOMAC total score improved from 59.5 ± 4.33 at baseline to 38.6 ± 4.50 at 1 month, 34.3 ± 4.45 at 3 months, 30.6 ± 3.06 at 6 months, and 28.5 ± 2.51 at 12 months after the final injection, corresponding to a mean 12-month within-patient change of −31.0 points (95% CI −32.58 to −29.42; −52.1%). Mean pain improved from 12.6 ± 1.35 to 5.6 ± 0.70, stiffness from 4.7 ± 0.48 to 2.1 ± 0.32, and physical function from 42.2 ± 2.62 to 20.8 ± 2.15. All 10 patients had lower WOMAC total scores at 12 months than at baseline. Friedman tests were significant for all four WOMAC domains (all p ≤ 5.05 × 10−7); Wilcoxon signed-rank tests versus baseline reached the theoretical minimum p at n = 10 (Bonferroni-adjusted p = 7.81 × 10−3) at every follow-up timepoint. No serious adverse events were documented; mild transient post-procedural soreness occurred in three patients. Conclusions: In this small retrospective pilot cohort, ultrasound-guided posteromedial fascial–periarticular injection was associated with sustained improvement in WOMAC pain, stiffness, physical function, and total scores over 12 months. These findings are preliminary and hypothesis-generating; non-specific effects including placebo, regression to the mean, and natural symptomatic fluctuation cannot be excluded. Prospective controlled trials are required to establish safety, reproducibility, mechanism, and comparative effectiveness.
- Open Access
- 10 February 2024
- Published by Elsevier in Journal of ISAKOS
- Vol. 9 (3) , 302-308
Optimal assessment for anterior talofibular ligament injury utilizing stress ultrasound entails internal rotation during plantarflexion
- 10 February 2024
- Published by Elsevier in Journal of ISAKOS
- Vol. 9 (3) , 302-308
Open AccessOptimal assessment for anterior talofibular ligament injury utilizing stress ultrasound entails internal rotation during plantarflexion
- 23 January 2024
- Published by Springer Nature in Surgical and Radiologic Anatomy
- Vol. 46 (2) , 241-248
Ultrasound-guided injection of the ankle joint: cadaveric investigation of the anterolateral approach
Objective Injection of the tibiotalar (TT) joint is commonly performed in clinical practice under ultrasound (US) guidance using an anteromedial approach. However, in some patients, this approach may be technically challenging due to post-traumatic and/or degenerative bony changes. Therefore, the aim of this cadaveric investigation was to demonstrate the feasibility of the ultrasound-guided (USG) injection of the ankle joint via the anterolateral sulcus (ALS) by confirming the dye placement/distribution inside the articular space. Likewise, the safety of the procedure has also been evaluated by measuring the distance between the needle and the intermediate dorsal cutaneous nerve of the foot. Design A descriptive laboratory study with eight embalmed cadaveric ankles using the Fix for Life (F4L) method was performed at the setting of an academic institution. The interventional technique and the related anatomical findings were illustrated. During the injection, the needle was advanced into the TT joint through the ALS under US guidance, i.e., in-plane anterior-to-posterior approach. With the objective to confirm its correct placement, the needle was kept in situ and—to demonstrate the location of the dye inside the articular space—all eight ankles were injected with 3 mL of green color dye. Thereafter, a layer-by-layer anatomical dissection was performed on all four cadavers. Results The position of the needle’s tip within the ALS was confirmed in all specimens. Accurate placement of the dye inside the articular space of the ankle was confirmed in seven of the eight cadaveric ankles, with 87.5% of accuracy. Herewith, unintentional spilling of the dye within the superficial soft tissues was reported in two of the eight ankles (25.0%). The mean distance between the needle and the intermediate dorsal cutaneous nerve of the foot, measured in all eight procedures, was 3 cm. Conclusion USG injection of the ALS using the in-plane, anterior-to-posterior approach can accurately place the injectate inside the articular space. Clinical relevance This cadaveric investigation described the accuracy and potential pitfalls of USG injection of the ankle via the anterolateral approach which represents an alternative technique in patients with reduced accessibility of the anteromedial recess due to degenerative and/or post-traumatic bony changes.
- 23 January 2024
- Published by Springer Nature in Surgical and Radiologic Anatomy
- Vol. 46 (2) , 241-248
Ultrasound-guided injection of the ankle joint: cadaveric investigation of the anterolateral approach
Objective Injection of the tibiotalar (TT) joint is commonly performed in clinical practice under ultrasound (US) guidance using an anteromedial approach. However, in some patients, this approach may be technically challenging due to post-traumatic and/or degenerative bony changes. Therefore, the aim of this cadaveric investigation was to demonstrate the feasibility of the ultrasound-guided (USG) injection of the ankle joint via the anterolateral sulcus (ALS) by confirming the dye placement/distribution inside the articular space. Likewise, the safety of the procedure has also been evaluated by measuring the distance between the needle and the intermediate dorsal cutaneous nerve of the foot. Design A descriptive laboratory study with eight embalmed cadaveric ankles using the Fix for Life (F4L) method was performed at the setting of an academic institution. The interventional technique and the related anatomical findings were illustrated. During the injection, the needle was advanced into the TT joint through the ALS under US guidance, i.e., in-plane anterior-to-posterior approach. With the objective to confirm its correct placement, the needle was kept in situ and—to demonstrate the location of the dye inside the articular space—all eight ankles were injected with 3 mL of green color dye. Thereafter, a layer-by-layer anatomical dissection was performed on all four cadavers. Results The position of the needle’s tip within the ALS was confirmed in all specimens. Accurate placement of the dye inside the articular space of the ankle was confirmed in seven of the eight cadaveric ankles, with 87.5% of accuracy. Herewith, unintentional spilling of the dye within the superficial soft tissues was reported in two of the eight ankles (25.0%). The mean distance between the needle and the intermediate dorsal cutaneous nerve of the foot, measured in all eight procedures, was 3 cm. Conclusion USG injection of the ALS using the in-plane, anterior-to-posterior approach can accurately place the injectate inside the articular space. Clinical relevance This cadaveric investigation described the accuracy and potential pitfalls of USG injection of the ankle via the anterolateral approach which represents an alternative technique in patients with reduced accessibility of the anteromedial recess due to degenerative and/or post-traumatic bony changes.
- 9 August 2023
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 31 (11) , 4791-4797
Harvest location has a minimal impact on differences in cross‐sectional area of quadriceps tendon in anterior cruciate ligament reconstruction
Purpose: Anterior cruciate ligament (ACL) reconstruction with quadriceps tendon (QT) has been gaining popularity. However, it is unknown how differences in harvest location of the QT affect its thickness and cross‐sectional area (CSA). The present study aimed to clarify the differences in thickness and CSA of the QT based on location of tendon harvesting.Methods: Patients scheduled for, or who underwent, ACL reconstruction were prospectively included in the study. The short‐axis images on ultrasound were used to assess the CSA of the QT at 30 and 60 mm proximal to the superior pole of the patella. QT autografts with CSAs greater than or equal to 10 mm of width were included and measured at three different locations, namely the center, medial one‐third, and lateral one‐third at the widest diameter of the QT. Patients with less than 10‐mm width of the QT at 60 mm proximal to the superior pole of the patella were excluded. The thickness and CSA were compared based on the location of tendon harvest.Results: Thirty‐seven patients were recruited for the study. The mean thickness and CSA were larger in the center of the QT compared to the lateral one‐third at 30 mm proximal to the superior pole of the patella (thickness, 6.7 ± 1.3 mm vs. 5.9 ± 1.3 mm; P = 0.009; CSA, 65.6 ± 11.4 mm2 vs. 58.8 ± 11.9 mm2; P = 0.036). There were no significant differences in thickness and CSA of the QT among the three assessment locations at 60 mm proximal to the superior pole of the patella (n.s.).Conclusion: The thickness and CSA of QT was greater in the center compared to the lateral one‐third at 30 mm proximal to the QT insertion point. However, the difference in value was clinically non‐significant, and therefore, harvest location of the QT autograft may not meaningfully impact intraoperative graft diameter. As a result, surgeons may choose the harvest location without concern for resultant graft diameter as long as the enough length of QT is secured.Level of evidence: III.
- 9 August 2023
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 31 (11) , 4791-4797
Harvest location has a minimal impact on differences in cross‐sectional area of quadriceps tendon in anterior cruciate ligament reconstruction
Purpose: Anterior cruciate ligament (ACL) reconstruction with quadriceps tendon (QT) has been gaining popularity. However, it is unknown how differences in harvest location of the QT affect its thickness and cross‐sectional area (CSA). The present study aimed to clarify the differences in thickness and CSA of the QT based on location of tendon harvesting.Methods: Patients scheduled for, or who underwent, ACL reconstruction were prospectively included in the study. The short‐axis images on ultrasound were used to assess the CSA of the QT at 30 and 60 mm proximal to the superior pole of the patella. QT autografts with CSAs greater than or equal to 10 mm of width were included and measured at three different locations, namely the center, medial one‐third, and lateral one‐third at the widest diameter of the QT. Patients with less than 10‐mm width of the QT at 60 mm proximal to the superior pole of the patella were excluded. The thickness and CSA were compared based on the location of tendon harvest.Results: Thirty‐seven patients were recruited for the study. The mean thickness and CSA were larger in the center of the QT compared to the lateral one‐third at 30 mm proximal to the superior pole of the patella (thickness, 6.7 ± 1.3 mm vs. 5.9 ± 1.3 mm; P = 0.009; CSA, 65.6 ± 11.4 mm2 vs. 58.8 ± 11.9 mm2; P = 0.036). There were no significant differences in thickness and CSA of the QT among the three assessment locations at 60 mm proximal to the superior pole of the patella (n.s.).Conclusion: The thickness and CSA of QT was greater in the center compared to the lateral one‐third at 30 mm proximal to the QT insertion point. However, the difference in value was clinically non‐significant, and therefore, harvest location of the QT autograft may not meaningfully impact intraoperative graft diameter. As a result, surgeons may choose the harvest location without concern for resultant graft diameter as long as the enough length of QT is secured.Level of evidence: III.
- Open Access
- 6 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (7) , 1922
Angiogenesis and Tissue Repair Depend on Platelet Dosing and Bioformulation Strategies Following Orthobiological Platelet-Rich Plasma Procedures: A Narrative Review
Angiogenesis is the formation of new blood vessel from existing vessels and is a critical first step in tissue repair following chronic disturbances in healing and degenerative tissues. Chronic pathoanatomic tissues are characterized by a high number of inflammatory cells; an overexpression of inflammatory mediators; such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1); the presence of mast cells, T cells, reactive oxygen species, and matrix metalloproteinases; and a decreased angiogenic capacity. Multiple studies have demonstrated that autologous orthobiological cellular preparations (e.g., platelet-rich plasma (PRP)) improve tissue repair and regenerate tissues. There are many PRP devices on the market. Unfortunately, they differ greatly in platelet numbers, cellular composition, and bioformulation. PRP is a platelet concentrate consisting of a high concentration of platelets, with or without certain leukocytes, platelet-derived growth factors (PGFs), cytokines, molecules, and signaling cells. Several PRP products have immunomodulatory capacities that can influence resident cells in a diseased microenvironment, inducing tissue repair or regeneration. Generally, PRP is a blood-derived product, regardless of its platelet number and bioformulation, and the literature indicates both positive and negative patient treatment outcomes. Strangely, the literature does not designate specific PRP preparation qualifications that can potentially contribute to tissue repair. Moreover, the literature scarcely addresses the impact of platelets and leukocytes in PRP on (neo)angiogenesis, other than a general one-size-fits-all statement that “PRP has angiogenic capabilities”. Here, we review the cellular composition of all PRP constituents, including leukocytes, and describe the importance of platelet dosing and bioformulation strategies in orthobiological applications to initiate angiogenic pathways that re-establish microvasculature networks, facilitating the supply of oxygen and nutrients to impaired tissues.
- 6 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (7) , 1922
Open AccessAngiogenesis and Tissue Repair Depend on Platelet Dosing and Bioformulation Strategies Following Orthobiological Platelet-Rich Plasma Procedures: A Narrative Review
Angiogenesis is the formation of new blood vessel from existing vessels and is a critical first step in tissue repair following chronic disturbances in healing and degenerative tissues. Chronic pathoanatomic tissues are characterized by a high number of inflammatory cells; an overexpression of inflammatory mediators; such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1); the presence of mast cells, T cells, reactive oxygen species, and matrix metalloproteinases; and a decreased angiogenic capacity. Multiple studies have demonstrated that autologous orthobiological cellular preparations (e.g., platelet-rich plasma (PRP)) improve tissue repair and regenerate tissues. There are many PRP devices on the market. Unfortunately, they differ greatly in platelet numbers, cellular composition, and bioformulation. PRP is a platelet concentrate consisting of a high concentration of platelets, with or without certain leukocytes, platelet-derived growth factors (PGFs), cytokines, molecules, and signaling cells. Several PRP products have immunomodulatory capacities that can influence resident cells in a diseased microenvironment, inducing tissue repair or regeneration. Generally, PRP is a blood-derived product, regardless of its platelet number and bioformulation, and the literature indicates both positive and negative patient treatment outcomes. Strangely, the literature does not designate specific PRP preparation qualifications that can potentially contribute to tissue repair. Moreover, the literature scarcely addresses the impact of platelets and leukocytes in PRP on (neo)angiogenesis, other than a general one-size-fits-all statement that “PRP has angiogenic capabilities”. Here, we review the cellular composition of all PRP constituents, including leukocytes, and describe the importance of platelet dosing and bioformulation strategies in orthobiological applications to initiate angiogenic pathways that re-establish microvasculature networks, facilitating the supply of oxygen and nutrients to impaired tissues.
- Open Access
- 12 June 2023
- Published by MDPI AG in Preprints.org
Angiogenesis and Tissue Repair Depend on Platelet Dosing and Bioformulation Strategies Following Orthobiological Platelet-Rich Plasma Procedures. A Narrative Review
Angiogenesis is new blood vessel formation from existing vessels and is a critical first step in tissue repair following chronic disturbances in healing and degenerative tissues. Chronic pathoanatomic tissues are characterized by a high number of inflammatory cells, overexpression of inflammatory mediators, such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1), the presence of mast cells, T cells, reactive oxygen species, and matrix metalloproteinases, and a decreased angiogenic capacity. Multiple studies have demonstrated that autologous orthobiological cellular preparations (e.g., platelet-rich plasma [PRP]) im-prove tissue repair and regenerate tissues. There are many PRP devices on the market. Unfortunately, they differ greatly in platelet numbers, cellular composition, and bioformulation. PRP is a platelet concentrate consisting of a high concentration of platelets with or without certain leukocytes, platelet-derived growth factors (PGFs), cytokines, molecules, and signaling cells. Several PRP products have immunomodulatory capacities that can influence resident cells in a diseased microenvironment, inducing tissue repair or re-generation. Generally, PRP is a blood-derived product, regardless of its platelet number and bioformulation, and the literature indicates both positive and negative patient treatment outcomes. Strangely, the literature does not designate specific PRP preparation qualifications that can potentially contribute to tissue re-pair. Moreover, the literature scarcely addresses the impact of platelets and leukocytes in PRP on (neo)angiogenesis other than a general one-size-fits-all statement that “PRP has angiogenic capabilities.” Here, we review the cellular composition of all PRP constituents, including leukocytes, and describe the importance of platelet dosing and bioformulation strategies in orthobiological applications to initiate angiogenic pathways that re-establish microvasculature networks, facilitating the supply of oxygen and nutrients to impaired tissues.
- 12 June 2023
- Published by MDPI AG in Preprints.org
Open AccessAngiogenesis and Tissue Repair Depend on Platelet Dosing and Bioformulation Strategies Following Orthobiological Platelet-Rich Plasma Procedures. A Narrative Review
Angiogenesis is new blood vessel formation from existing vessels and is a critical first step in tissue repair following chronic disturbances in healing and degenerative tissues. Chronic pathoanatomic tissues are characterized by a high number of inflammatory cells, overexpression of inflammatory mediators, such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1), the presence of mast cells, T cells, reactive oxygen species, and matrix metalloproteinases, and a decreased angiogenic capacity. Multiple studies have demonstrated that autologous orthobiological cellular preparations (e.g., platelet-rich plasma [PRP]) im-prove tissue repair and regenerate tissues. There are many PRP devices on the market. Unfortunately, they differ greatly in platelet numbers, cellular composition, and bioformulation. PRP is a platelet concentrate consisting of a high concentration of platelets with or without certain leukocytes, platelet-derived growth factors (PGFs), cytokines, molecules, and signaling cells. Several PRP products have immunomodulatory capacities that can influence resident cells in a diseased microenvironment, inducing tissue repair or re-generation. Generally, PRP is a blood-derived product, regardless of its platelet number and bioformulation, and the literature indicates both positive and negative patient treatment outcomes. Strangely, the literature does not designate specific PRP preparation qualifications that can potentially contribute to tissue re-pair. Moreover, the literature scarcely addresses the impact of platelets and leukocytes in PRP on (neo)angiogenesis other than a general one-size-fits-all statement that “PRP has angiogenic capabilities.” Here, we review the cellular composition of all PRP constituents, including leukocytes, and describe the importance of platelet dosing and bioformulation strategies in orthobiological applications to initiate angiogenic pathways that re-establish microvasculature networks, facilitating the supply of oxygen and nutrients to impaired tissues.
- 19 January 2023
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 102 (5) , 449-453
The International Olympic Committee Venue Ultrasound Program
The objective of this pilot investigation was to describe the novel use of venue ultrasound at the 2020 Tokyo Olympic Games. Portable laptop ultrasound machines were made available to cover seven Olympic sports at seven venues. The responses by both the National Olympic Committee personnel accompanying the medical room visits and by the examining physicians were recorded. Athletes were followed up until the end of the Olympic Games and the ultrasound diagnostic accuracy was evaluated. Fourteen athletes were evaluated using venue ultrasound and the recorded injuries included seven soft tissue, five osseous, and two nonmusculoskeletal injuries. From these, eight athletes were evaluated further by other imaging modalities, which indicated that the ultrasound provided an accurate diagnosis in all cases. All National Olympics Committee personnel reported increased diagnostic confidence and felt that venue ultrasound should be considered for future sports events. Furthermore, all evaluating physicians felt ultrasound was helpful in refining the diagnosis. The average years of sports ultrasound experience was 8.4 yrs and the average years of clinical sports medicine experience was 9.3 yrs among the physicians. In conclusion, the International Olympic Committee Venue Ultrasound Pilot Program showed promise in improving venue triaging, suggesting its role at future sports events.
- 19 January 2023
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 102 (5) , 449-453
The International Olympic Committee Venue Ultrasound Program
The objective of this pilot investigation was to describe the novel use of venue ultrasound at the 2020 Tokyo Olympic Games. Portable laptop ultrasound machines were made available to cover seven Olympic sports at seven venues. The responses by both the National Olympic Committee personnel accompanying the medical room visits and by the examining physicians were recorded. Athletes were followed up until the end of the Olympic Games and the ultrasound diagnostic accuracy was evaluated. Fourteen athletes were evaluated using venue ultrasound and the recorded injuries included seven soft tissue, five osseous, and two nonmusculoskeletal injuries. From these, eight athletes were evaluated further by other imaging modalities, which indicated that the ultrasound provided an accurate diagnosis in all cases. All National Olympics Committee personnel reported increased diagnostic confidence and felt that venue ultrasound should be considered for future sports events. Furthermore, all evaluating physicians felt ultrasound was helpful in refining the diagnosis. The average years of sports ultrasound experience was 8.4 yrs and the average years of clinical sports medicine experience was 9.3 yrs among the physicians. In conclusion, the International Olympic Committee Venue Ultrasound Pilot Program showed promise in improving venue triaging, suggesting its role at future sports events.
- Open Access
- 1 October 2022
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 49 (4) , 513-515
Ultrasound-guided surgery in musculoskeletal medicine
- 1 October 2022
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 49 (4) , 513-515
Open AccessUltrasound-guided surgery in musculoskeletal medicine
- Open Access
- 1 February 2022
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 41 (10) , 2395-2412
Recommended Musculoskeletal and Sports Ultrasound Terminology: A Delphi‐Based Consensus Statement
Objectives: The current lack of agreement regarding standardized terminology in musculoskeletal and sports ultrasound presents challenges in education, clinical practice, and research. This consensus was developed to provide a reference to improve clarity and consistency in communication.Methods: A multidisciplinary expert panel was convened consisting of 18 members representing multiple specialty societies identified as key stakeholders in musculoskeletal and sports ultrasound. A Delphi process was used to reach consensus which was defined as group level agreement >80%.Results: Content was organized into seven general topics including: 1) General Definitions, 2) Equipment and Transducer Manipulation, 3) Anatomic and Descriptive Terminology, 4) Pathology, 5) Procedural Terminology, 6) Image Labeling, and 7) Documentation. Terms and definitions which reached consensus agreement are presented herein.Conclusions: The historic use of multiple similar terms in the absence of precise definitions has led to confusion when conveying information between colleagues, patients, and third‐party payers. This multidisciplinary expert consensus addresses multiple areas of variability in diagnostic ultrasound imaging and ultrasound‐guided procedures related to musculoskeletal and sports medicine.
- 1 February 2022
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 41 (10) , 2395-2412
Open AccessRecommended Musculoskeletal and Sports Ultrasound Terminology: A Delphi‐Based Consensus Statement
Objectives: The current lack of agreement regarding standardized terminology in musculoskeletal and sports ultrasound presents challenges in education, clinical practice, and research. This consensus was developed to provide a reference to improve clarity and consistency in communication.Methods: A multidisciplinary expert panel was convened consisting of 18 members representing multiple specialty societies identified as key stakeholders in musculoskeletal and sports ultrasound. A Delphi process was used to reach consensus which was defined as group level agreement >80%.Results: Content was organized into seven general topics including: 1) General Definitions, 2) Equipment and Transducer Manipulation, 3) Anatomic and Descriptive Terminology, 4) Pathology, 5) Procedural Terminology, 6) Image Labeling, and 7) Documentation. Terms and definitions which reached consensus agreement are presented herein.Conclusions: The historic use of multiple similar terms in the absence of precise definitions has led to confusion when conveying information between colleagues, patients, and third‐party payers. This multidisciplinary expert consensus addresses multiple areas of variability in diagnostic ultrasound imaging and ultrasound‐guided procedures related to musculoskeletal and sports medicine.